A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Lung Cancer, Nonsmall CellAdvanced CancerAdvanced Solid Tumor
- Interventions
- Registration Number
- NCT04237805
- Lead Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Brief Summary
The study comprises two phases: phase I dose escalation (including PK run-in period and treatment period) and phase II study.
- Detailed Description
This is a multicenter, single-arm, open-label dose-finding phase I/II study to determine the MTD and RP2D of oral foritinib succinate monotherapy in patients with advanced ALK-positive malignant solid tumor, and to evaluate the safety, tolerability, and PK characteristics of SAF-189s in patients with advanced ALK-positive NSCLC. Phase II clinical study was conducted to evaluate the efficacy, tumor activity, and safety of remitinib succinate in patients with ALK/ROS1 positive advanced non-small cell lung cancer, and to preliminary evaluate the population pharmacokinetic characteristics of remitinib succinate.
This study consisted of two phases: phase I (including PK induction and continuous administration) and phase II, Phase I dose escalation : the patients with advanced ALK-positive malignant solid tumor who have progressed on standard therapies; Phase I study: histologically or cytologically confirmed, locally advanced ALK-positive and/or metastatic stage IIIB/IV NSCLC who have progressed on standard therapy; Phase II Study Part I: Patients with histologically and/or cytologically confirmed ALK or ROS1 positive locally-advanced and/or metastatic stage IIIb \~IV NSCLC;Patients who had not previously received or had received only one ALK/ROS1 inhibitor for disease progression or intolerance, and who had no more than 3 previous treatment lines overall Phase II Study Part Ⅱ: cohort1：ROS1-positive locally advanced and/or metastatic stage IIIB\~IV NSCLC patients diagnosed histologically and/or cytologically, with no prior systemic therapy or only one line of non-ROS1-inhibitor treatment cohort 2: patients with histologically and/or cytologically confirmed ROS1-positive locally advanced and/or metastatic stage IIIb \~IV NSCLC who had previously only received crizotinib as a ROS1 inhibitor for disease progression or intolerance and had no more than 3 overall previous treatment lines；
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 280
-
Have a full understanding of this study and voluntarily sign an informed consent form (ICF) 2）Phase I dose escalation : the patients with advanced ALK-positive malignant solid tumor who have progressed on standard therapies; Phase I study: histologically or cytologically confirmed, locally advanced ALK-positive and/or metastatic stage IIIB/IV NSCLC who have progressed on standard therapy; Phase II Study Part I: Patients with histologically and/or cytologically confirmed ALK or ROS1 positive locally-advanced and/or metastatic stage IIIb ~IV NSCLC;Patients who had not previously received or had received only one ALK/ROS1 inhibitor for disease progression or intolerance, and who had no more than 3 previous treatment lines overall Phase II Study Part Ⅱ: cohort1：ROS1-positive locally advanced and/or metastatic stage IIIB~IV NSCLC patients diagnosed histologically and/or cytologically, with no prior systemic therapy or only one line of non-ROS1-inhibitor treatment cohort 2: patients with histologically and/or cytologically confirmed ROS1-positive locally advanced and/or metastatic stage IIIb ~IV NSCLC who had previously only received crizotinib as a ROS1 inhibitor for disease progression or intolerance and had no more than 3 overall previous treatment lines； 3) At least one measurable lesion per RECIST1.1; Note: a lesion previously treated by radiotherapy is not considered as a target lesion, unless confirmed progression is documented after radiotherapy.
-
ECOG performance score ≤ 2; 5) Male or female patients ≥ 18 and ≤ 75 years old in Phase I ；Male or female patients ≥ 18 in Phase II 6) Life expectancy ≥ 12 weeks; 7) Patient with appropriate organ function as documented by:
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;
- Hemoglobin ≥ 90 g/L;
- Platelets (PLT) ≥ 100 × 109/L
- Serum total bilirubin ≤ 1.5 × ULN (if the patient has Gilbert's syndrome, ≤ 3 × ULN and direct bilirubin ≤ 1.5 × ULN);
- Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN for patient with liver metastases);
- Creatinine clearance (CrCL) ≥ 50 mL/min (calculated by Cockcroft-Gault equation)
- Fasting blood glucose ≤ 200 mg/dL (≤ 11.1 mmol/L) 8) Toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 per NCI-CTCAE (Version 4.03), exception of alopecia; 9）Within 21 days prior to enrolment, women of reproductive age had to confirm a negative serological pregnancy test and agree to use an effective contraceptive method for all study drug use and for 28 days after the last dose.For the purposes of this protocol, women of childbearing age are defined as sexually mature women who: 1) have not undergone hysterectomy or bilateral oophorectomy, or 2) have natural menopause that has not lasted continuously for 24 months (amenorrhea after cancer treatment does not exclude fertility) (i.e., have had menstruation at any time during the previous consecutive 24 months);
-
Has had prior chemotherapy, anti-cancer treatment with biological drugs, or other investigational agents within 28 days or received TKI or targeted therapies within 14 days prior to enrollment;
-
Received radiotherapy within 21 days prior to the 1st dose or continuance of toxicities due to prior radiotherapy that do not recover to Grade 0 or 1;
-
Patients who received major surgery within 3 weeks before enrollment or have not adequately recovered from prior surgery;
-
Patients with central nervous system (CNS) metastases requiring
- Clinical local intervention such as surgical excision, radiotherapy or other therapies
- Phase I dose escalation: patients requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) are not eligible for dose escalation study (not applicable to patients participating Phase I cohort expansion or Phase II).
-
Diabetics without stable control and with insulin therapy (patients with fasting blood glucose below 7mmol/L, who are receiving stable hypoglycemic drug regimen, and whose blood glucose control is stable as evaluated by specialist doctors are allowed to be enrolled); 6）Difficulty in swallowing or having an active digestive disorder or having undergone major gastrointestinal surgery may significantly affect the administration or absorption of SAF189s (e.g. ulcerative lesions, uncontrollable nausea, vomiting, diarrhoea, malabsorption syndrome, and enteroctomies) 7）Patients who are taking the following medicines:
- Repaglinide (cytochrome [CYP]2C8) and drugs metabolized via CYP3A4 enzyme within 1 week before enrollment;
- Medicines which are known to cause QT prolongation or torsade de pointes;
- Coumarin anticoagulants within 1 week before enrollment (low molecular weight heparin is permitted);
- Illegal drugs;
- Has a history of acute pancreatitis within 1 year before enrollment, or past history of chronic pancreatitis; 9) Patients have positive laboratory test for anti-HCV, or are diagnosed with human immunodeficiency virus (HIV) infection, or who refuse to receive HIV screen test; 10) Patients have other malignant tumor history or with other malignant tumors simultaneously; 11) Impairment of cardiac function or clinically significant heart disease, including New York College of Cardiology (NYHA) grade ≥ 3 congestive heart failure, arrhythmias, conduction abnormalities requiring treatment, cardiomyopathy, or uncontrolled hypertension； 12) Corrected QT interval using Fridericia formula > 450 msec for male patients and > 470 msec for female patients; 13) Patients have uncured interstitial lung disease history or non-infectious pneumonitis prior to enrollment, except for those induced by radiation therapy; 14）Any other clinically significant disease or condition (such as uncontrolled diabetes, active or uncontrolled infections, etc.) that the investigator believes could affect protocol adherence or affect the patient's ability to sign up for ICF; 15）Spinal cord metastases with potential risk or symptoms of spinal cord compression； 16）The second cohort received ROS1 inhibitors other than crizotinib； 17）The patient had uncontrollable amounts of pleural effusion, ascites, and pericardial effusion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SAF-189s SAF-189s The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.
- Primary Outcome Measures
Name Time Method ORR until 6 months' treatment of the last patients in each cohort Objective response rate
DLT 24 days after the first dose in the dose escalation phase Dose Limiting Toxicity incidence within 24 days after the first dose in the dose escalation phase
- Secondary Outcome Measures
Name Time Method PFS 3 years Progression-free survival (PFS)
TEAE through study completion, an average of 3 year TEAE incidence, types, grade of toxicity according to NCI-CTCAE (version 5.0); study-related TEAE, SAE, study-related SAE, ≥ Grade 3 TEAE, ≥ Grade 3 TESAE, and TEAE leading to permanent discontinuation.
CNS responses 4 years Central nervous system efficacy evaluation，（time to CNS progression，CNS TTP），（CNS objective response rate，CNS ORR）,（duration of CNS response，CNS DOR）
OS 4 years Overall survival (OS)
CBR 3 years clinical benefit rate (CBR)
DOR 3 years duration of response (DoR)
Cmax 1 years Maximum Plasma Concentration
Trial Locations
- Locations (41)
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Beijing Chest Hospital,Capital Medical University
🇨🇳Beijing, Beijing, China
The Fourth Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
Jilin Cancer Hospital
🇨🇳Jilin, Jilin, China
Guangdong Province People's General Hospital
🇨🇳Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, Guangdong, China
Shanghai Chest Hospital,Shanghai Jiaotong University
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
🇨🇳Zhengzhou, Henan, China
Jiangsu Province Hospital
🇨🇳Nanjing, Jiangsu, China
SIR RUN RUN SHAW HOSPITAL Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Zhengzhou Central Hospital
🇨🇳Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The Central Hospital of Yongzhou
🇨🇳Yongzhou, Hunan, China
The First Hospital of Jilin University
🇨🇳Changchun, Jilin, China
Yanbian University Affiliated Hospital
🇨🇳Yanji, Jilin, China
Linyi Cancer Hospital
🇨🇳Linyi, Shandong, China
West China Hospital，Sichuan University
🇨🇳Chengdu, Sichuan, China
The second peoples hospital of Neijiang
🇨🇳Neijiang, Sichuan, China
Shandong Provincial Qianfoshan Hospital
🇨🇳Jinan, Shandong, China
Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
🇨🇳Changsha, Hunan, China
General Hospital of Xuzhou Mining Group
🇨🇳Xuzhou, Jiangsu, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
No. 960 Hospital of the Joint Service Support Force of Chinese People's Liberation Army
🇨🇳Jinan, Shandong, China
Jieyang Peoples Hospital
🇨🇳Jieyang, Shanxi, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
The first affiliated hospital of China medical university
🇨🇳Shenyang, Liaoning, China
Tianjin Medical University Cancer Hospital
🇨🇳Tianjin, Tianjin, China
Tianjin Peoples Hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital, Medical School of Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Shulan (Hangzhou) Hospital
🇨🇳Hangzhou, Zhengjiang, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
he First Affiliated Hospital of Bengbu Medical College
🇨🇳Bengbu, Anhui, China
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
🇨🇳Shenzhen, Guangdong, China
Affiliated Hospital of Hebei University
🇨🇳Baoding, Hebei, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Hubei Cancer Hospital
🇨🇳Wuhan, Hubei, China
The second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China